US 12,337,064 B2
Formulations and compositions for ortho- and/or retro-nasal delivery and associated systems, methods and articles
David A. Edwards, Cambridge, MA (US); and Tom Devlin, Somerville, MA (US)
Assigned to SENSORY CLOUD, INC., Boston, MA (US)
Appl. No. 17/273,689
Filed by SENSORY CLOUD, LLC, Boston, MA (US)
PCT Filed Sep. 4, 2019, PCT No. PCT/US2019/049541
§ 371(c)(1), (2) Date Mar. 4, 2021,
PCT Pub. No. WO2020/096686, PCT Pub. Date May 14, 2020.
Claims priority of provisional application 62/727,123, filed on Sep. 5, 2018.
Prior Publication US 2021/0315811 A1, Oct. 14, 2021
Int. Cl. A61K 9/00 (2006.01); A23L 33/105 (2016.01); A61K 31/045 (2006.01); A61K 31/202 (2006.01); A61K 31/465 (2006.01); A61K 35/00 (2006.01); A61K 36/185 (2006.01); A61K 36/22 (2006.01); A61K 36/42 (2006.01); A61K 36/54 (2006.01); A61K 36/73 (2006.01); A61K 36/752 (2006.01); A61K 36/81 (2006.01); A61K 36/8962 (2006.01); A61K 36/899 (2006.01); A61K 36/9068 (2006.01); A61K 45/06 (2006.01); A61M 11/00 (2006.01); A61M 15/00 (2006.01); A61M 15/08 (2006.01)
CPC A61K 9/0078 (2013.01) [A23L 33/105 (2016.08); A61K 31/045 (2013.01); A61K 31/202 (2013.01); A61K 31/465 (2013.01); A61K 35/00 (2013.01); A61K 36/185 (2013.01); A61K 36/22 (2013.01); A61K 36/42 (2013.01); A61K 36/54 (2013.01); A61K 36/73 (2013.01); A61K 36/752 (2013.01); A61K 36/81 (2013.01); A61K 36/8962 (2013.01); A61K 36/899 (2013.01); A61K 36/9068 (2013.01); A61K 45/06 (2013.01); A61M 11/003 (2014.02); A61M 15/0003 (2014.02); A61M 15/009 (2013.01); A61M 15/08 (2013.01); A23V 2002/00 (2013.01); A61M 2205/0294 (2013.01); A61M 2205/50 (2013.01)] 12 Claims
 
1. A composition for ortho-nasal or retro-nasal food or therapeutic applications, the composition comprising:
an aerosol of droplets dispensed from a nebulizer, the aerosol of droplets having a mass median droplet size of from 3 μm to 20 μm, the droplets of the aerosol of droplets comprising an amount of water or a mixture of water and alcohol and which carry agonists or antagonists of all of: transient receptor potential vanilloid (TRPV) receptors, olfactory receptors, and taste receptors, and wherein a concentration of all agonists or antagonists in the composition is in a range of 50 μg/mL to 2 mg/mL, the composition delivered ortho-nasally and/or retro-nasally as the aerosol of droplets from the nebulizer.